Literature DB >> 20601926

PharmGKB summary: fluoropyrimidine pathways.

Caroline F Thorn1, Sharon Marsh, Michelle Whirl Carrillo, Howard L McLeod, Teri E Klein, Russ B Altman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 20601926      PMCID： PMC3098754          DOI： 10.1097/FPC.0b013e32833c6107

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  60 in total

1.  Known variant DPYD alleles do not explain DPD deficiency in cancer patients.

Authors:  E S Collie-Duguid; M C Etienne; G Milano; H L McLeod
Journal:  Pharmacogenetics       Date:  2000-04

2.  A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation.

Authors:  Salvatore Terrazzino; Marco Agostini; Salvatore Pucciarelli; Lara Maria Pasetto; Maria Luisa Friso; Alessandro Ambrosi; Veronica Lisi; Alberta Leon; Mario Lise; Donato Nitti
Journal:  Pharmacogenet Genomics       Date:  2006-11       Impact factor: 2.089

3.  Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy.

Authors:  S T Pullarkat; J Stoehlmacher; V Ghaderi; Y P Xiong; S A Ingles; A Sherrod; R Warren; D Tsao-Wei; S Groshen; H J Lenz
Journal:  Pharmacogenomics J       Date:  2001       Impact factor: 3.550

Review 4.  Capecitabine: fulfilling the promise of oral chemotherapy.

Authors:  Jimmy J Hwang; John L Marshall
Journal:  Expert Opin Pharmacother       Date:  2002-06       Impact factor: 3.889

5.  Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines.

Authors:  Deliang Cao; Rosalind L Russell; Dekai Zhang; Janine J Leffert; Giuseppe Pizzorno
Journal:  Cancer Res       Date:  2002-04-15       Impact factor: 12.701

6.  Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.

Authors:  Victor Cohen; Valerie Panet-Raymond; Nelly Sabbaghian; Isabelle Morin; Gerald Batist; Rima Rozen
Journal:  Clin Cancer Res       Date:  2003-05       Impact factor: 12.531

Review 7.  5-fluorouracil: mechanisms of action and clinical strategies.

Authors:  Daniel B Longley; D Paul Harkin; Patrick G Johnston
Journal:  Nat Rev Cancer       Date:  2003-05       Impact factor: 60.716

8.  Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance.

Authors:  Rita Humeniuk; Lata G Menon; Prasun J Mishra; Richard Gorlick; Rebecca Sowers; Wojciech Rode; Giuseppe Pizzorno; Yung-Chi Cheng; Nancy Kemeny; Joseph R Bertino; Debabrata Banerjee
Journal:  Mol Cancer Ther       Date:  2009-04-21       Impact factor: 6.261

9.  MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer.

Authors:  S Afzal; S A Jensen; B Vainer; U Vogel; J P Matsen; J B Sørensen; P K Andersen; H E Poulsen
Journal:  Ann Oncol       Date:  2009-05-22       Impact factor: 32.976

10.  Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil.

Authors:  Christophe Kunz; Frauke Focke; Yusuke Saito; David Schuermann; Teresa Lettieri; Jim Selfridge; Primo Schär
Journal:  PLoS Biol       Date:  2009-04-28       Impact factor: 8.029
View more
  37 in total

1.  Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.

Authors:  Bart A W Jacobs; Maarten J Deenen; Dick Pluim; J G Coen van Hasselt; Martin D Krähenbühl; Robin M J M van Geel; Niels de Vries; Hilde Rosing; Didier Meulendijks; Artur M Burylo; Annemieke Cats; Jos H Beijnen; Alwin D R Huitema; Jan H M Schellens
Journal:  Br J Clin Pharmacol       Date:  2016-06-03       Impact factor: 4.335

2.  Pharmacogenomics meets precision cardio-oncology: is there synergistic potential?

Authors:  Jennifer K Hockings; Jessica A Castrillon; Feixiong Cheng
Journal:  Hum Mol Genet       Date:  2020-10-20       Impact factor: 6.150

3.  PharmGKB: the Pharmacogenomics Knowledge Base.

Authors:  Caroline F Thorn; Teri E Klein; Russ B Altman
Journal:  Methods Mol Biol       Date:  2013

Review 4.  FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.

Authors:  Beatrice Mohelnikova-Duchonova; Bohuslav Melichar; Pavel Soucek
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

5.  Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.

Authors:  Michela Roberto; Adriana Romiti; Andrea Botticelli; Federica Mazzuca; Luana Lionetto; Giovanna Gentile; Ida Paris; Rosa Falcone; Maria Bassanelli; Francesca Romana Di Pietro; Concetta Elisa Onesti; Elisabetta Anselmi; Serena Macrini; Maurizio Simmaco; Paolo Marchetti
Journal:  Eur J Clin Pharmacol       Date:  2016-11-18       Impact factor: 2.953

Review 6.  PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6.

Authors:  Ellen M McDonagh; Catherine Wassenaar; Sean P David; Rachel F Tyndale; Russ B Altman; Michelle Whirl-Carrillo; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-09       Impact factor: 2.089

Review 7.  Germline oncopharmacogenetics, a promising field in cancer therapy.

Authors:  Chiara Pesenti; Milena Gusella; Silvia M Sirchia; Monica Miozzo
Journal:  Cell Oncol (Dordr)       Date:  2015-01-09       Impact factor: 6.730

8.  Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.

Authors:  K E Caudle; C F Thorn; T E Klein; J J Swen; H L McLeod; R B Diasio; M Schwab
Journal:  Clin Pharmacol Ther       Date:  2013-08-29       Impact factor: 6.875

9.  Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses.

Authors:  Heather E Wheeler; Anna González-Neira; Guillermo Pita; Julio-Cesar de la Torre-Montero; Rosario Alonso; Luis A Lopez-Fernandez; Emilio Alba; Miguel Martín; M Eileen Dolan
Journal:  Pharmacogenet Genomics       Date:  2014-05       Impact factor: 2.089

10.  A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.

Authors:  Dan Rosmarin; Claire Palles; Alistair Pagnamenta; Kulvinder Kaur; Guillermo Pita; Miguel Martin; Enric Domingo; Angela Jones; Kimberley Howarth; Luke Freeman-Mills; Elaine Johnstone; Haitao Wang; Sharon Love; Claire Scudder; Patrick Julier; Ceres Fernández-Rozadilla; Clara Ruiz-Ponte; Angel Carracedo; Sergi Castellvi-Bel; Antoni Castells; Anna Gonzalez-Neira; Jenny Taylor; Rachel Kerr; David Kerr; Ian Tomlinson
Journal:  Gut       Date:  2014-03-19       Impact factor: 23.059
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.